Lateral Flow Assay for Complement Activation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring complement activation, such as traditional sandwich-type immunoassays, are limited by requiring laboratory processing, skilled technicians, and hours to produce results, leading to false positives and an inability to provide near real-time data essential for early intervention in traumatic injuries or diseases.
Innovation Solution
A lateral flow assay method that detects iC3b and intact C3 levels using specific non-cross-reactive antibodies, allowing for rapid determination of pathologic complement activation within 30 minutes, minimizing sample handling and activation, and distinguishing between pathological and non-pathological activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional sandwich-type immunoassays are used to measure complement activation, then measurement precision can be achieved, but the testing time is excessively long (hours) and false positives occur due to sample handling activation
Solution Approach 1:
The patent extracts the critical measurement function from complex traditional immunoassays by using a simplified turbidity-based detection method that measures complement activation directly through light scattering properties, eliminating the need for lengthy incubation and multiple processing steps while maintaining measurement accuracy
Solution Approach 2:
The patent changes the measurement parameter from specific antigen-antibody binding detection to turbidity/optical density measurement, which provides a rapid readout of complement activation status without requiring extended incubation periods or complex sample handling procedures
2Reliability
If traditional immunoassays with extensive sample handling are used, then comprehensive analysis can be performed, but false positive results occur due to in vitro complement activation during processing
Solution Approach 1:
The patent performs the measurement immediately upon sample collection using a simplified protocol that minimizes handling steps, thereby capturing the true in vivo complement activation status before any in vitro activation can occur during extended processing
Solution Approach 2:
The patent converts the natural turbidity property of activated complement samples into a beneficial measurement signal, where the very activation that causes false positives in traditional assays becomes the direct readout mechanism for accurate complement status detection
3Productivity
If rapid testing methods are used to provide near real-time data, then intervention time is reduced, but measurement precision and reliability may be compromised
Solution Approach 1:
The patent replaces the mechanical/chemical complexity of traditional immunoassays with a simple optical measurement system that reads turbidity changes, enabling rapid results without sacrificing the fundamental accuracy of complement activation detection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, accurate, and point-of-care measurement of complement activation, reducing false positives and providing timely diagnostic information for immediate patient care during critical events, such as traumatic injuries or autoimmune disorders.
Implementation Method 1
detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.